Shareholders Equity: The sum of preferred and common equity items.
Ensysce Biosciences, Inc. (ENSC) had Shareholders Equity of $2.88M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$5.07M |
|
$-10.18M |
|
-- |
|
$5.07M |
|
$15.31M |
|
$-10.24M |
|
$0.06M |
|
$-10.18M |
|
$-10.18M |
|
$-10.18M |
|
$-10.18M |
|
$-10.18M |
|
$-10.18M |
|
$-10.24M |
|
$-10.23M |
|
2.56M |
|
2.56M |
|
$-3.98 |
|
$-3.98 |
|
| Balance Sheet Financials | |
$7.24M |
|
$0.12M |
|
$0.21M |
|
$7.45M |
|
$4.57M |
|
-- |
|
-- |
|
$4.57M |
|
$2.88M |
|
$2.88M |
|
|
Shareholders Equity |
$2.88M |
4.58M |
|
| Cash Flow Statement Financials | |
$-7.81M |
|
$-0.12M |
|
$8.74M |
|
$3.50M |
|
$4.31M |
|
$0.81M |
|
$0.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.59 |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
100.00% |
|
-202.12% |
|
-202.12% |
|
-202.00% |
|
-200.85% |
|
-200.84% |
|
$-7.93M |
|
-- |
|
-- |
|
-- |
|
0.68 |
|
-- |
|
12.05 |
|
30.28 |
|
-352.76% |
|
-352.76% |
|
-136.55% |
|
-352.76% |
|
$0.63 |
|
$-3.10 |
|
$-3.05 |
|